Search alternatives:
point decrease » point increase (Expand Search)
mean decrease » a decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), teer decrease (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
Showing 521 - 540 results of 59,195 for search '(( 5 ((((nn decrease) OR (we decrease))) OR (mean decrease)) ) OR ( e point decrease ))', query time: 1.09s Refine Results
  1. 521
    Mean pain interference overtime (baseline to 12 weeks).

    Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 522
    Mean pain severity overtime (baseline to 12 weeks).

    Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 523
    Zebrafish PGRP5 exhibits differential expression characteristics under different bacterial stimuli.

    Zebrafish PGRP5 exhibits differential expression characteristics under different bacterial stimuli. by Xi Li (19208)

    Published 2025
    Save to List
    Saved in:
  4. 524
    Relish SUMOylation decreases its transcriptional activity.

    Relish SUMOylation decreases its transcriptional activity. by Ruijuan Tang (11250680)

    Published 2021
    Save to List
    Saved in:
  5. 525
    Fig 5 -

    Fig 5 - by Harshita Sharma (4836180)

    Published 2023
    Save to List
    Saved in:
  6. 526
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 527
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 528
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 529
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 530
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 531
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 532
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 533
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 534
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 535
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 536
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 537
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 538
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 539
    List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decrease of the mean in the diabetes group with respect to the control group; eta<sup>2</sup> is the proportion of the total variance that can be explained by the factor “diabetes” in the linear model; N is the number of valid data points that entered the analysis; the platform on which the corresponding metabolite was measured is indicated by the first letter of the provider: B = Biocrates, C = Chenomx, M = Metabolon.

    List of selected metabolites that associate with diabetes at q-values <0.05 using log-scaled metabolite concentrations and assuming a linear model; %change is the increase or decre... by Karsten Suhre (67967)

    Published 2010
    Save to List
    Saved in:
  20. 540
    Type and duration of leisure-time activities performed 5 years after RYGB.

    Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

    Published 2022
    Save to List
    Saved in:

Search Tools: